Skip to content

Study · Animal study (in vivo) · rat · 2008

8 results

GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1.

Yamamoto D, Ikeshita N, Matsubara T, Tasaki H, Herningtyas EH, Toda K, Iida K, Takahashi Y, Kaji H, Chihara K, Okimura Y

Life sciences5 Dec 2007Cited by 21 (Europe PMC)

PMID18191156 (opens in a new tab)DOI10.1016/j.lfs.2007.11.019 (opens in a new tab)PepBankPUB-18191156
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rats given dexamethasone, GHRP‑2 significantly attenuated the dexamethasone-induced increase in Atrogin-1 mRNA in soleus muscle.

    In plain wordsIn rats given a muscle-wasting drug, GHRP‑2 reduced the rise in Atrogin-1 gene activity in muscle.

    Peptide
    GHRP-2
    Outcome
    DecreaseAtrogin-1 mRNA in soleus muscle with dexamethasone
    Study

    ratn: not reported in source

    dexamethasone-induced muscle atrophy
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The increased mRNA level of Atrogin-1 was significantly attenuated by GHRP-2.
    1 context sentence
    Summary · context
    In the present study, effect of Growth Hormone Releasing Peptide-2 (GHRP-2), a GH secretagogue receptor (GHS-R) agonist, on the expressions of Atrogin-1 and MuRF1 in vivo rat muscles was examined.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats, GHRP‑2 decreased MuRF1 mRNA level irrespective of the presence of dexamethasone.

    In plain wordsIn rats, GHRP‑2 lowered MuRF1 gene activity in muscle, with or without a muscle-wasting drug.

    Peptide
    GHRP-2
    Outcome
    DecreaseMuRF1 mRNA in muscle
    Study

    ratn: not reported in source

    rat muscle
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, GHRP-2 decreased MuRF1 mRNA level irrespective of the presence of dexamethasone.
    1 context sentence
    Summary · context
    In the present study, effect of Growth Hormone Releasing Peptide-2 (GHRP-2), a GH secretagogue receptor (GHS-R) agonist, on the expressions of Atrogin-1 and MuRF1 in vivo rat muscles was examined.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats, GHRP‑2 did not influence plasma IGF-I levels.

    In plain wordsIn rats, GHRP‑2 did not change blood IGF-I levels.

    Peptide
    GHRP-2
    Outcome
    No significant changePlasma IGF-I
    Study

    ratn: not reported in source

    rat muscle
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although IGF-I is a well-known protective factor for muscle atrophy, GHRP-2 did not influence plasma IGF-I levels and IGF-I mRNA levels in muscles.
    1 context sentence
    Summary · context
    In the present study, effect of Growth Hormone Releasing Peptide-2 (GHRP-2), a GH secretagogue receptor (GHS-R) agonist, on the expressions of Atrogin-1 and MuRF1 in vivo rat muscles was examined.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats, GHRP‑2 did not influence IGF-I mRNA levels in muscles.

    In plain wordsIn rats, GHRP‑2 did not change IGF-I gene activity in muscle.

    Peptide
    GHRP-2
    Outcome
    No significant changeIGF-I mRNA in muscle
    Study

    ratn: not reported in source

    rat muscle
    Outcome group
    Growth hormone and IGF-1 · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although IGF-I is a well-known protective factor for muscle atrophy, GHRP-2 did not influence plasma IGF-I levels and IGF-I mRNA levels in muscles.
    1 context sentence
    Summary · context
    In the present study, effect of Growth Hormone Releasing Peptide-2 (GHRP-2), a GH secretagogue receptor (GHS-R) agonist, on the expressions of Atrogin-1 and MuRF1 in vivo rat muscles was examined.
  5. 05LabIn vitro (cells)Mechanism

    In differentiated C2C12 myocytes, GHRP‑2 attenuated dexamethasone-induced Atrogin-1 expression dose-dependently.

    In plain wordsIn muscle cells in the lab, GHRP‑2 reduced the rise in Atrogin-1 caused by a muscle-wasting drug, more so at higher doses.

    Peptide
    GHRP-2
    Outcome
    DecreaseDexamethasone-induced Atrogin-1 mRNA in C2C12 myocytes
    Study

    n: not reported in source

    differentiated C2C12 myocytes
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GHRP-2 attenuated dexamethasone-induced expression of them dose-dependently and decreased the basal level of MuRF1 mRNA.
    1 context sentence
    Summary · context
    To clarify a direct effect of GHRP-2, differentiated C2C12 myocytes were used.
  6. 06LabIn vitro (cells)Mechanism

    In differentiated C2C12 myocytes, GHRP‑2 attenuated dexamethasone-induced MuRF1 expression dose-dependently.

    In plain wordsIn muscle cells in the lab, GHRP‑2 reduced the rise in MuRF1 caused by a muscle-wasting drug, more so at higher doses.

    Peptide
    GHRP-2
    Outcome
    DecreaseDexamethasone-induced MuRF1 mRNA in C2C12 myocytes
    Study

    n: not reported in source

    differentiated C2C12 myocytes
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GHRP-2 attenuated dexamethasone-induced expression of them dose-dependently and decreased the basal level of MuRF1 mRNA.
    1 context sentence
    Summary · context
    To clarify a direct effect of GHRP-2, differentiated C2C12 myocytes were used.
  7. 07LabIn vitro (cells)Mechanism

    In differentiated C2C12 myocytes, GHRP‑2 decreased the basal level of MuRF1 mRNA.

    In plain wordsIn muscle cells in the lab, GHRP‑2 lowered baseline MuRF1 gene activity.

    Peptide
    GHRP-2
    Outcome
    DecreaseBasal MuRF1 mRNA in C2C12 myocytes
    Study

    n: not reported in source

    differentiated C2C12 myocytes
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GHRP-2 attenuated dexamethasone-induced expression of them dose-dependently and decreased the basal level of MuRF1 mRNA.
    1 context sentence
    Summary · context
    To clarify a direct effect of GHRP-2, differentiated C2C12 myocytes were used.
  8. 08LabIn vitro (cells)Mechanism

    In differentiated C2C12 myocytes, the GHRP‑2 suppression of Atrogin-1 and MuRF1 expression was blocked by the GHS-R1a blocker [D-Lys(3)]-GHRP-6.

    In plain wordsIn muscle cells in the lab, a ghrelin receptor blocker stopped GHRP‑2 from lowering Atrogin-1 and MuRF1.

    Peptide
    GHRP-2
    Outcome
    Not applicableBlockade of GHRP-2 effect on Atrogin-1 and MuRF1 by GHS-R1a blocker
    Study

    n: not reported in source

    differentiated C2C12 myocytes
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The suppressive effect on the expressions of Atrogin-1 and MuRF1 by GHRP-2 was blocked by [D-Lys(3)]-GHRP-6, a GHS-R1a blocker, suggesting the effect of GHRP-2 was mediated through GHS-R1a.
    1 context sentence
    Summary · context
    To clarify a direct effect of GHRP-2, differentiated C2C12 myocytes were used.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.